TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Optimal minute ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With 1 Point Improvement on MMVS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pectoralis Minor Length (PML)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Scapular Distance (TSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protracted shoulder posture (supine measurement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protracted shoulder posture (standing measurement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Health Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: STD incidence
Endpoint domain: Adverse events/effects
Primary endpoint: incidence/attack rate of diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: IUD Usage Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Amyloid load in brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: drug-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Median time on treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Standard Ethanol Content Units (SECs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol Drink Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days Involved in Productive Work Activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Safety and tolerability of Keppra
Endpoint domain: Adverse events/effects
Primary endpoint: Postnatal depression severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Adult ADHD Investigator Symptom Rating Scale (AISRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with RVLA below or equal to 2.1 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of medical complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients alive and progression-free at 7 months
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity of IGTT for diabetes diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Specificity of IGTT for diabetes diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sensitivity of HOMA-%IR for diabetes diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Specificity of HOMA-%IR for diabetes diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: proportion of patients with a 90-day modified Rankin Scale (mRS) score below 2
Endpoint domain: Mortality/survival
Primary endpoint: Myocardial insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of cardio-vascular efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physician burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of standard drinks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Concentration (Cav)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability [AUCτ]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in blood pressure (SBP and DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maternal postpartum depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal parenting stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parenting confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sum of Pain Intensity Differences Over 8 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual Risk Behavior Change
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Mental Health Outcome Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Protection against COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Pain while walking on flat surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants completing challenge with insignificant adverse result
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute change from baseline in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response evaluated using modified Severity of Alopecia Tool (mSALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial Blood Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in iGFR (Glomerular Filtration Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Ankle Foot Volume (AFV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thigh muscle CSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Time to Recovery of T4/T1 Ratio to 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 20% Improvement According to American College of Rheumatology Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall adherence to the exercise protocol as measured by average time in HIIT intervals for HIIT groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to the exercise protocol as measured by average time in the target heart rate (THR) zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade ≥3 adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Median Progression-Free Survival (PFS) Thalidomide
Endpoint domain: Mortality/survival
Primary endpoint: Median Progression-Free Survival (PFS) Celecoxib
Endpoint domain: Mortality/survival
Primary endpoint: Median Progression-Free Survival (PFS) Isotretinoin
Endpoint domain: Mortality/survival
Primary endpoint: Area under concentration time-curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma drug concentration versus time curve (AUCo-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of PSA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate pain control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events at the injection site (target knee)
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Device Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in tapping speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in number of apps used
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in time spent using the smartphone
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in speed of unlocking the smartphone
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attainment of independent oral feeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of MRI and venous ultrasonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Booster Responses to Diphtheria and Tetanus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Booster Responses to Anti-PT, FHA and Anti-PRN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers for Antibodies to Poliovirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: micro RNA extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total asthma control questionnaire (ACQ) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Trough Seated Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients that require discontinuation of drug because of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with bowel movement within four hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: free T4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Levels of heat shock proteins in serum and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Engagement in Recommended Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total Dose of Follicular Stimulating Hormone (FSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Occupational Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Arterial blood gases (ABGs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Power of Attention Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days to stop bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AM-PAC Basic Mobility score at Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AM-PAC Basic Mobility score at Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle tone tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fatigue index of muscle
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Disease Control (CR, PR, or SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Park-based Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Gene expression regulation in preterm delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Blood-plasma concentration of Beta-lactam antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lipids from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Long term efficacy evaluated by ASAS criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term safety evaluated by immunogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Long term safety evaluated by clinical laboratory test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor blood flow measured by ASL MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Attitudes towards sodium claims
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Understanding of oat fibre claims
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in number of unprotected anal sex acts
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Reduction in number of sex partners
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: GABA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Small Dense Low-density Lipoprotein Cholesterol (sdLDL-C) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Doubling of serum creatinine level from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Progression to end stage renal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Executive Functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Focused and Sustained Attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Verbal Working Memory and Learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Verbal and Non-Verbal Reasoning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with complete and partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability assessment score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total dose of lidocaine administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Metabolic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proliferative Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug effectiveness assessed using ADHD rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug effectiveness assessed using CGI -S (Clinical Global Impression - Severity scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug effectiveness assessed using CGI-I (Clinical Global Impression - Improvement scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Antibody Titers ≥ 10 1/Dilution Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Antibody Titers ≥ 40 1/Dilution Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline local immune effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adolescents' Perceived Risk of Drug Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adolescents' Likelihood of Drug Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revised Behavioral Problem checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of secondary cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of MACCEs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Who Achieved Clinical Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Baroreflex Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful Treatment Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC From Time Zero to Time t (AUC[0-tlast])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Highest dose tolerated without inducing vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of fungicidal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Inter-eye ganglion cell layer thickness (GCL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with GCL IED <= 8 microns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Antenatal Attachment Scale (MAAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Paternal Antenatal Attachment Scale (PAAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to successful ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient reported outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weighted Modified Rankin Scale (mRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Independence (mRS 0-2)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Stroke-related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Abnormalities in vital sign assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormalities in ECG assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thrombin generation - peak amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacokinetics of naproxcinod and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anemia of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: M Value (Insulin Stimulated Glucose Uptake)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardio-metabolic risks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With AEs of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Healthy Eating Index (HEI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neurodevelopmental evaluations (Bayley Scores MDI and PDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum torque around the knee joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Progressive neurological disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Itch Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Start of Relief of Symptoms From HAE Attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving ACR20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Responders (Primary Medical Treatment in Arm 1, Primary Surgical Treatment in Arm 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Responders (All Treatments)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Experiencing Treatment Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Peak plasma level of gut hormones after meal ingestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Food intake following gut hormone infusion compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nasopharyngeal and esophageal temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of recurrence after treatment with PPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Response rate to the treatment with PPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in evaluation of a public performance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Correlation of social feedback processing with neural indices and anxiety levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUCt of CKD-330, D086, CKD-333
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of CKD-330, D086, CKD-333
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects reporting solicited injection-site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects reporting solicited systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With an Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes